Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Zella R. Zeigler"'
Autor:
Charles Srodes, Jane M. Raymond, Ibrahim Sbeitan, Richard K. Shadduck, Dennis Meisner, John Lister, Cynthia Evans, Jeffrey Gryn, Zella R. Zeigler
Publikováno v:
Leukemia Research. 26:893-897
Patients with myelodysplastic syndromes (MDS) who were anemic and/or thrombocytopenic were treated with 5-azacytidine (5-AZA) at a dose of 75 mg/m(2) per day SQ x 7 days. This cycle was repeated every 28 days. Forty-eight patients who received at lea
Publikováno v:
American Journal of Clinical Oncology. 20:189-192
A Phase II clinical trial was undertaken using roquinimex (Linomide) in patients with myelodysplastic syndromes (MDS). Roquinimex is an orally active drug with immunostimulating activities demonstrated in vitro and clinically. Seventeen patients with
Publikováno v:
American Journal of Hematology. 42:217-220
This report describes objective improvement in two patients with poorly responsive thrombotic thrombocytopenic purpura (TTP) syndromes (with cryosupernatant). The first had a partial response to plasma exchange with whole plasma (fresh frozen plasma;
Publikováno v:
STEM CELLS. 11:562-567
In vitro studies may serve as a guide to clinical strategies with cytokines. In this study, marrows from 26 patients with myelodysplastic syndrome (MDS) were assayed for myeloid progenitor cells in agar gel. Colony stimulating activity was provided b
Publikováno v:
American Journal of Kidney Diseases. 21:31-37
There are data suggesting that recombinant human erythropoietin (rHuEPO) may induce thromboses in hemodialysis patients, possibly due to alterations in platelet function. In an earlier study, we found evidence of platelet hyperfunction in several pat
Publikováno v:
Cancer. 65:2624-2630
The effectiveness and toxicities of high-dose cytosine arabinoside with L-asparaginase (HiDAC-ASNase) were evaluated in 41 patients with "poor risk" acute nonlymphocytic leukemia (ANLL). Twenty-four patients had either refractory or relapsed primary
Autor:
Zella R. Zeigler
Publikováno v:
Thrombosis and Haemostasis. 63:371-374
SummaryThe present studies measured bleeding times, without venous occlusion, in a series of patients, whose bleeding times (+ venostasis) consistently exceeded 20 min. During these tests, the amount of blood loss (expressed as mg/min) was also quant
Publikováno v:
Transplantation. 60(7)
L-Leucyl-L-leucine methyl ester (LLME) is a lysosomatropic compound that is converted by dipeptidyl peptidase I to metabolites that are membranolytic for cytotoxic T cells, NK cells, and LAK cells. Ex vivo treatment of murine marrow with LLME amelior
Autor:
Wally Meyer, Richard K. Shadduck, Zella R. Zeigler, Linda W. Jennings, Craig S. Rosenfeld, John Nemunaitis, Florence Boegel, Laura Getty
Publikováno v:
American journal of clinical oncology. 18(3)
Tumor necrosis factor (TNF) inhibits hematopoietic cell proliferation. The combination of pentoxifylline (PTX) and ciprofloxacin (Cipro) has been previously shown to reduce circulating serum levels of TNF. In this Phase II trial 14 patients with adva
Publikováno v:
Stem cells (Dayton, Ohio). 11(1)
Sixteen patients (ages 53 to 85) with myelodysplastic syndrome (MDS) were treated with recombinant human erythropoietin (rHuEPO) to observe its effects on hematopoiesis. All were transfusion dependent and had Hb levels less than 9.0 g/dl and less tha